Four senior professionals in the medical circle who have their own business, after experiencing the actual combat of various projects and becoming a well-known successful person in the industry, what would they want to do? Yu Zhong, the chairman of the plaque vision, told Hunting.com: "We have no interest in making money on the market by simply selling a product. We want to launch a good project to make the project company IPO. This is a Fun is also a challenge." Technology obtains FDA and CFDA clinical application approval, accurate diagnosis of vascular arteriosclerotic plaque vulnerability In 2013, after repeated investigations and months of discussions, several founders agreed that the clinical diagnosis field, especially in the field of increasingly declining drug sales, is of great clinical significance. There are still great opportunities for special inspection projects. But first, the technological advancement of the project must be recognized by the entire industry. The clinical application of the project must be easy to popularize and supported by academic leaders. The clinical application must have a clear selling point, be operational, and can be implemented. At this time, the vascular plaque qualitative quantitative analysis system (MRI-PlaqueView) of the previously vulnerable US plaque diagnostic company (VPDiagnostics. Inc.) was approved by the US Food and Drug Administration (FDA) for clinical application. It has also been approved by the China Food and Drug Administration (CFDA) for clinical application and can be used for clinical promotion in China and the United States. According to the public, the magnetic resonance vulnerable plaque diagnosis (MR-VPD) technique uses non-interventional methods to analyze the magnetic resonance images of arteriosclerotic plaques through the MRI-PlaqueView system, so as to accurately assess the vulnerability of the plaque and judge the brain. The probability of a stroke. This technique can be used to visually measure: plaque composition, plaque load, and plaque bleeding, which are important indicators for determining plaque vulnerability. This method is also useful for judging whether treatment is effective. This technology has been researched for many years and was VPDiagnostics Inc. in 2008. Commercialized for clinical diagnosis. (Respondents for the picture) Looking at the carotid plaques in China, according to a study published in Eur J Prev Cardiol in 2017, about one-third of Chinese adults have carotid plaques. Just as tumors are classified as benign and malignant, vascular plaques are also classified as stable and vulnerable. Vulnerable plaques are high-risk. High-risk plaques may break or fall, which may cause blockage of the distal teleports of the brain. The occurrence of stroke in the brain. But people with plaques usually don't know if their plaque is a high-risk plaque. Nowadays, there are many clinically common methods of vascular plaque examination, such as ultrasound, CT, magnetic resonance, DSA and so on. Yuzhong and the team's core personnel agree that all of these methods can determine the presence or absence of plaque and assess the degree of lumen stenosis caused by plaque, but the analysis of the wall structure is limited, and the vulnerable nature of the plaque is not available. Diagnose directly. As far as doctors are concerned, only the rate of stenosis is used as a basis for diagnosis. The rate of missed diagnosis or misdiagnosis is high. The obvious stenosis may not be high-risk. Many cases without obvious stenosis are very high-risk. The MR-VPD examination can look at the tube wall in a cross-sectional form, qualitatively and quantitatively analyze the plaque components, and the detection accuracy can reach more than 95%. 10 months to deploy 114 hospitals in more than 20 provinces in China, reversely wholly-owned and acquired the original technology company In March 2014, Yuzhong and three other medical professionals established a plaque horizon and became VPDiagnostic. Inc. is a sales agency in China. In the 10 months of 2015, the plaque horizon has deployed more than 114 hospitals in more than 20 provinces with the largest market demand in the country. The initial experience users are the top three hospitals in each region. In October 2016, it received 20 million rounds of round A financing. Yuzhong told Hunting.com that there is still a technology similar to MR-VPD, but in the global market, China has the largest market share. MRI-PlaqueView is the only product that has both FDA and CFDA certification, and the plaque horizon The team has strong market resources and sales experience in the Chinese market. Thus, almost at the same time, the plaque horizon reversed the wholly-owned acquisition of VPDiagnostics. Inc, owns all the technology, research and development and patents of the company. (Respondents for the picture) At present, the Magnetic Resonance Vulnerable Plaque Diagnostic Project (MR-VPD) has also received approval from the Health and Planning Commission and the National Development and Reform Commission in nine provinces including Hebei and Anhui, and 18 public hospitals have been officially introduced and repurchased. In addition to public hospitals, there are also well-known private hospitals, third-party medical imaging diagnostic centers, cloud imaging platforms and China's largest health check-up group. "The business characteristics of the public medical sector are relatively slow, but the total amount is larger. So after three years, the company's sales performance will have more than 50% of the profits from the public medical sector," Yuzhong said. Compatible with mainstream brand of nuclear magnetic resonance equipment, launching a pay-per-view business model Since MRI-PlaqueView is a technical system, it is first necessary for the hospital to use the existing nuclear magnetic resonance machine to collect patient data, and then submit the data to the MRI-PlaqueView system of the plaque horizon for analysis, and finally the system directly provides the conclusion to the hospital's clinical. Doctors. In this process, data is transmitted between multiple independent systems, and there are multiple solutions. Therefore, MRI-PlaqueView does not intrude into the original equipment, nor does it require the authorization of the original equipment manufacturer. Different from the equipment category, MRI-PlaqueView charges the customer according to the number of times used. When one patient is used to use the software once, the bill is charged once; for 1 million patients, the software needs to be used 1 million times. According to the 1 million-time billing, the customer can purchase a certain number of times in advance according to the need, and then buy it again, or pay the fee according to the actual number of quarterly statistics. As of now, MRI-PlaqueView has been used more than 20,000 times. Yuzhong (for respondents) The company's four core executive teams are over 40 years old. They have served as executives in pharmaceutical companies, and more than half have successful entrepreneurial experience. Yuzhong told Hunting.com that the founder team is older, has a strong professional background, and has a long experience, which makes the founder team's evaluation of the project deeper than pure financial investors. But this is also a disadvantage of the company. The drawback is that it is bound by too much industry experience, obviously lacks the sense of innovation that young people are not limited, and is slow to respond to some current trends. Be careful. Although they are more diligent than young people, they dare to say that the degree of activity is too different. There is a very young generation in the company. The younger generation is undergoing tempering and hopes to grow as soon as possible. At present, the research center in Seattle is still carrying out product development and version update. There are about 20 people in Beijing office, mainly responsible for market support, such as sales training for each provincial vendor and technical use training for hospital clinicians. In the future, the plaque horizon will continue to focus on the diagnosis of vascular arteriosclerotic plaque, but different development directions are planned. The first is to develop into more application fields, from carotid artery to vertebral artery basilar artery, coronary artery expansion, and many more. The second is to extend to more advanced imaging technologies for more time-saving magnetic resonance 3D scanning technology. The third is to implement a more intelligent version based on AI technology, improve the diagnostic speed, reduce the diagnostic technology requirements for doctors, and reduce the training cost for customers. The plaque horizon is currently valued at 350 million and is preparing for A+ round financing, hoping that the financing amount will be 35 million. The new financing will be fully used for market expansion, including the expansion of the team and the development of new business areas. The core goal is to rapidly increase the company's profitability.
Organic kale powder is processed from fresh kale. We strive to produce the best quality kale powder in the world. The entire production process is 100% organic and traceable.
Organic kale cultivation requires the following conditions. Our organic kale is planted in Hebei province, where the climate conditions are very suitable for kale growth.
1. Opulent sunshine.
Main processing technic: organic fresh kale, cut, clean air bubble wash, slice, dewatering and drying, steam sterilization (Temperature:>95°C Time:2′), powder.
1. 100% organic
Kale Powder,Organic Kale Cultivation,Organic Kale Powder,Air Dried Kale Powder Organicway (xi'an) Food Ingredients Inc. , https://www.organicwayinc.com
2. Tastes best after a frost, so plant in early spring or late summer.
3. Sow kale from seed or nursery stock in late summer for a fall harvest or early spring for summer harvest. Sow seeds 1/2 inch deep, allowing 1 foot between plants and 2 feet between rows.
4. Mulch around kale plants with a heavy layer of garden compost. This keeps the soil cool, prevents moisture loss, and provides readily available nutrients to the shallow feeder roots.
Organic kale powder characteristics
2. non-GMO
3. Gluten-free
4. allergen-free
5. 100% pure vegetable powder without any additive
6. Fine kale powder